Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 22;108(11):2273–2280. doi: 10.1111/cas.13392

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

A critical factor associated with vascular remodeling effect induced by eribulin in multiple human cancer xenograft models. Increase of microvessel density (MVD) was defined as a parameter for vascular remodeling effect of eribulin. Eribulin (ERI, 1.5 mg/kg) was given to mice at day 0 by tail vein injection. (a) Antitumor effects of eribulin in 10 human cancer xenograft models (n = 6 for each group). (b) MVD at 7 days after treatment of eribulin in 10 human cancer xenograft models (n = 3). (c) Representative immunohistochemical staining with CD31 (tumor vessel) and alpha‐smooth muscle actin (α‐SMA) (pericyte) in H460 and H1975 xenografted tumors. Majority of vessels were not covered by pericytes. Brown, CD31, red, α‐SMA. (d) Correlation between enhancement of vascular remodeling (MVD) and antitumor effects of eribulin. *P < 0.05.